Thymosin alpha-1
ImmuneApproved for other indicationsTα1 · Zadaxin
A thymic peptide with approved use in some countries. Logged in milligrams, typically a few times per week.
- Typical form
- Lyophilized vial
- Typical route
- Subcutaneous
- Display unit
- mg
- Typical vial
- 1.6 mg
- Half-life (approx.)
- 2 h
- Default in-use window
- 28 days
Labeled / commonly logged
Typical protocol
A snapshot of how this compound is logged — not a prescription. You set every number.
- Common range
- 1.6–3.2 mg
- Starting log
- 1.6 mg
- Cadence
- Custom weekdays
- Timing
- Twice weekly, milligram scale
- Duration
- Several weeks in community logs
Thymalfasin is approved in some countries at 1.6 mg. Research vials are not that product. Confirm the label milligrams — vials are small.
Reconstitution note
Small vials. Confirm label milligrams before mixing.
Storage
Fridge after mix.
Cautions
Regional approvals do not make research vials equivalent.
Evidence posture
Approved as thymalfasin in some markets.